Intrexon raises $160M in IPO

In Maryland, Intrexon Corporation today announced the pricing of its initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and offering expenses.

All of the common stock is being offered by Intrexon.  The shares are expected to begin trading on the New York Stock Exchange on Thursday, August 8, 2013, under the symbol “XON.”

Intrexon Corporation is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.

In addition, Intrexon has granted the underwriters a 30-day option to purchase up to 1,499,999 additional shares of common stock from Intrexon.
J.P. Morgan and Barclays are acting as joint book-running managers for the offering.  Griffin Securities and Mizuho Securities are acting as co-managers.

Intrexon’s Better DNA approach, according to the firm, means realizing better products and processes through the industrial engineering of synthetic biology.
With its suite of proprietary and complementary technologies, Intrexon can precisely control the amount, location, and modification of biological molecules; work in many cell types in multiple organisms, from microbe to mammal, in vitro or in vivo; and develop novel approaches across a broad spectrum of end markets.